{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:31:45Z","timestamp":1790875905685,"version":"4.1.0"},"reference-count":51,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Angioimmunoblastic T\u2010cell lymphoma (AITL) is a common type of peripheral T\u2010cell lymphoma (PTCL) with a poor prognosis, and an effective first\u2010line therapy is lacking. Chidamide is a selective histone deacetylase inhibitor and has been approved by the China Food and Drug Administration for relapsed or refractory PTCL. We conducted a multicenter phase II clinical trial combining chidamide with prednisone, etoposide, and thalidomide (CPET regimen) for a total of eight cycles in untreated AITL patients in China. The primary objectives were the overall response rate (ORR) and complete remission (CR) rate after eight cycles of the CPET regimen. The secondary endpoints were progression\u2010free survival (PFS) and safety. Of the 71 enrolled patients, 51 completed the eight cycles of the CPET regimen. The ORR and CR of the 51 patients were 90.2 and 54.9%, respectively. After a median follow\u2010up of 11.4\u00a0months (95% confidence interval [CI], 9.9\u201317.0), the median PFS of the 51 patients was 42.6\u00a0months (95% CI, 27.7\u2014not reached) and the median overall survival (OS) was not reached. The 2\u2010year PFS rate and OS rate were 66.5 and 82.2%, respectively. Sixty\u2010eight patients received at least one cycle of CPET regimen and were included as the safety assessment population. The most common grade 3\/4 adverse event was neutropenia (<jats:italic>n<\/jats:italic>\u00a0=\u00a022, 32.3%). Twelve patients showed treatment\u2010related infections and recovered from antibiotic therapy; the other adverse events were mostly mild and reversible. The oral CPET regimen is an effective, tolerable, and economical choice for untreated AITL in a Chinese population. This trial was registered in <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.clinicaltrails.gov\">www.clinicaltrials.gov<\/jats:ext-link> as NCT03273452.<\/jats:p>","DOI":"10.1002\/ajh.26499","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T06:22:49Z","timestamp":1644992569000},"page":"623-629","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T\u2010cell lymphoma in a Chinese population: A multicenter phase <scp>II<\/scp> trial"],"prefix":"10.1002","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3623-9235","authenticated-orcid":false,"given":"Yawen","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology the Affiliated Hospital of Qingdao University  Qingdao China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Zhengzhou University  Zhengzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Hematology the Affiliated Hospital of Qingdao University  Qingdao China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5447-3282","authenticated-orcid":false,"given":"Qingqing","family":"Cai","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine Sun Yat\u2010Sen University Cancer Center  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhua","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology The Second Hospital of Dalian Medical University  Dalian China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Center, West China Hospital Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma Tianjin Medical University Cancer Institute and Hospital  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology the Affiliated Hospital of Qingdao University  Qingdao China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Hematology the Affiliated Hospital of Qingdao University  Qingdao China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-692541"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP7YLTQPUSDQ5C"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0990-y"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2016.12.001"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.5402\/2011\/623924"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv237"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802233165"},{"issue":"8","key":"e_1_2_9_10_1","first-page":"ECR44","article-title":"Successful treatment of refractory angioimmunoblastic T\u2010cell lymphoma with thalidomide and dexamethasone","volume":"91","author":"Ramasamy K","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403710"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2016.1219820"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2009-0"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-05-0194"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-021-00203-8"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-105759"},{"issue":"11","key":"e_1_2_9_19_1","first-page":"915","article-title":"Clinical characteristics and prognosis in 84 patients with angioimmunoblastic T\u2010cell lymphoma: a single\u2010center analysis","volume":"41","author":"Li TT","year":"2020","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16447"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.061507"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003081"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-074641"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.06.003"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00023-X"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2"},{"issue":"4","key":"e_1_2_9_27_1","first-page":"1466","article-title":"A comprehensive analysis of RHOA mutation positive and negative angioimmunoblastic T\u2010cell lymphomas by targeted deep sequencing, expression profiling and single cell digital image analysis","volume":"46","author":"Butzmann ASK","year":"2020","journal-title":"Int J Mol Med"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2873"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25450"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00511"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2872"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-531509"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.5376"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-020-00962-x"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.06.003"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2017.05.006"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000773"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2016.12.013"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1753044"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0243-8"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2782"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2320"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001285"},{"key":"e_1_2_9_45_1","unstructured":"WeiS.Clinical analysis of Chidamide combined with etoposide prednisone and thalidomide (C\u2010PET) regimen in the treatment of AITL patients [in Chinese]. Qingdao University Master's Thesis2019."},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568026615666150825140822"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.25615"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-230X(08)00406-5"},{"issue":"9","key":"e_1_2_9_49_1","first-page":"846","article-title":"Immunomodulatory drugs (IMiDs) in multiple myeloma","volume":"17","author":"Raza S","year":"2017","journal-title":"Curr Cancer Drug Targets"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061451"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1984.tb03318.x"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003217"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26499","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.26499","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26499","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T17:37:22Z","timestamp":1692812242000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.26499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,11]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1002\/ajh.26499"],"URL":"https:\/\/doi.org\/10.1002\/ajh.26499","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,11]]},"assertion":[{"value":"2021-11-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}